Sanofi (MIL:1SAN) Short-Term Capital Lease Obligation

: €253 Mil (As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

Sanofi's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was €253 Mil.

Sanofi's quarterly Short-Term Capital Lease Obligation increased from Jun. 2022 (€231 Mil) to Dec. 2022 (€277 Mil) but then declined from Dec. 2022 (€277 Mil) to Jun. 2023 (€253 Mil).

Sanofi's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€269 Mil) to Dec. 2022 (€277 Mil) but then declined from Dec. 2022 (€277 Mil) to Dec. 2023 (€275 Mil).

Sanofi Short-Term Capital Lease Obligation Historical Data

The historical data trend for Sanofi's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

261.00

269.00

277.00

275.00

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															269.00	231.00	277.00	253.00	275.00

Sanofi Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Sanofi Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sanofi's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (MIL:1SAN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (MIL:1SAN) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:USA SNY:Mexico 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi (MIL:1SAN) Headlines

No Headlines